



Pricing & Reimbursement/Market Access Working Group

Agenda

- 1 **Welcome / Meeting agenda**
- 2 **European collaboration between regulators and health technology assessment bodies: The EMA-EUnetHTA21 Joint Work Plan** (Marcus Guardian, EUnetHTA21)
 - The EMA and [EUnetHTA21](#) consortium of Member States' HTA bodies have published their joint work plan, which is aimed at preparing for the coming into application of the EU HTA Regulation in 2025.
 - The [plan outlines](#) priority areas, including joint scientific consultation for robust evidence generation, generation of patient relevant data to support decision making and information exchange on products of mutual interest, including advanced therapy medicinal products (ATMPs).
- 3 **SMARtCARE – a pan-European registry to collect real-life outcome data on patients with spinal muscular atrophy** (Timm Volmer, SmartStep)
- 4 **Denmark: Experiences from the new Danish cost-effectiveness evaluation process** (Mette Bøgelund, Incentive)
- 5 **RWE4Decisions: Multi-stakeholder collaborative approach to establish agreement on use of Real-World Data and create common frameworks for the use of Real-World Evidence (RWE)** (Marine Borchart, FIPRA)
 - [RWE4Decisions](#) is a multi-stakeholder initiative which brings stakeholders together to agree what real-world data could be collected for highly innovative technologies – when, by whom and how – in order to generate RWE that informs decisions by healthcare systems.
- 6 **Further country updates**
- 7 **AOB / End of meeting**